| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3342239 | Autoimmunity Reviews | 2009 | 6 Pages |
Abstract
Future alternative therapies of antiphospholipid syndrome are proposed to be based on the expanding knowledge of β2-GPI- and AnxA5-phospholipid interactions, specifically antagonizing β2-GPI receptors, as well as inhibiting their signaling pathways.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Mojca Frank, Snežna Sodin-Å emrl, Å pela Irman, Borut BožiÄ, Blaž Rozman,